ArticleThe oncologist2025
Barriers and facilitators to representative acute leukemia trial participation at National Cancer Institute-designated comprehensive cancer centers.
Article in The oncologist, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Development and pre-testing of a family-centered digital intervention to help families know what to EXPECT from pediatric acute lymphoblastic leukemia therapy.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026Article
- Review
- Interactive Medication Calendars to Support At-Home Care of Pediatric Patients With ALL.JCO clinical cancer informatics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundDemographic enrollment disparities in adult acute leukemia clinical trials limit generalizability and diminish opportunities for minoritized populations to benefit from novel therapies. The distinct natural history and clinical research landscape of acute leukemia, the latter of which is centralized at the National Cancer Institute-designated Comprehensive Cancer Centers (CCCs), pose challenges to eliminating this disparity. MATERIALS AND
methodsWe performed an analysis of 2 qualitative focus group and interview-based studies to characterize barriers and facilitators to representative acute leukemia clinical trial participation. Participants were patients with acute leukemia belonging to under-enrolled demographic groups (female, older adults, Hispanic ethnicity, or non-White race) and clinicians who treat and enroll them in clinical trials at CCCs in Massachusetts and Ohio.
resultsEight focus groups and 7 individual interviews were performed with 61 participants (34 patients and 27 clinicians). Barriers idiosyncratic to acute leukemia included inpatient and resource-intensive outpatient care, limited time between diagnosis and treatment initiation, low disease prevalence leading to trial centralization, and barriers related to hematopoietic stem cell transplantation. Barriers common across cancer types included restrictive eligibility criteria, complex study logistics, and cost. Potential solutions included local hospital and CCC partnerships and navigation to enhance timely referral and co-management during participation, multi-modal trial education and peer support in the peri-diagnostic period, minimizing unnecessary eligibility criteria, and travel and financial assistance.
conclusionsPatients and clinicians identified actionable steps to improve trial participation that address the unique challenges for adults with acute leukemia. A multi-pronged and disease-specific approach is needed to achieve representative acute leukemia clinical trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.